Compare iShares Global Tech ETF (IXN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Medpace Holdings Inc — how do they compare? iShares Global Tech ETF trades at $149.84 (market cap $10.03B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and iShares Global Tech ETF is more actively traded (286,617 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and Medpace Holdings Inc for 14 Days on average.
| IXN | MEDP | |
|---|---|---|
Market Cap | $10.03B | $16.82B |
Volume | 286,617 | 223,093 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $630.19 |
52-Week Low | $95.76 | $393.42 |
Typical Hold Time | 47 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN, the iShares Global Tech ETF, trades at $149.84, down 1.52% on the day but near its 52-week high of $151.40, indicating strong momentum. Technical signals are bullish overall, with moving averages supporting an uptrend, while oscillators remain neutral. Recent news highlights the ETF hitting new highs and trading at a high-teens P/E with a compelling long-term EPS growth outlook, though concentration and AI exposure pose risks.
The outlook for IXN is positive, driven by global tech diversification and AI growth opportunities, but investors face risks from portfolio concentration and market volatility. Wall Street sentiment is bullish, with analysts citing valuation compression and earnings potential as key catalysts for further gains.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
